Literature DB >> 32164487

Chromatin structure regulates cancer-specific alternative splicing events in primary HPV-related oropharyngeal squamous cell carcinoma.

Theresa Guo1, Kristina Diana A Zambo1, Fernando T Zamuner1, Tingting Ou1, Christopher Hopkins1, Dylan Z Kelley1, Hildegard A Wulf1, Eli Winkler1, Rossin Erbe2, Ludmila Danilova2,3, Michael Considine2, David Sidransky1,2, Alexander Favorov2,3, Liliana Florea4, Elana J Fertig2,5,6, Daria A Gaykalova1,2.   

Abstract

Human papillomavirus-related oropharyngeal squamous cell carcinoma (HPV+ OPSCC) represents a unique disease entity within head and neck cancer with rising incidence. Previous work has shown that alternative splicing events (ASEs) are prevalent in HPV+ OPSCC, but further validation is needed to understand the regulation of this process and its role in these tumours. In this study, eleven ASEs (GIT2, CTNNB1, MKNK2, MRPL33, SIPA1L3, SNHG6, SYCP2, TPRG1, ZHX2, ZNF331, and ELOVL1) were selected for validation from 109 previously published candidate ASEs to elucidate the post-transcriptional mechanisms of oncogenesis in HPV+ disease. In vitro qRT-PCR confirmed differential expression of 9 of 11 ASE candidates, and in silico analysis within the TCGA cohort confirmed 8 of 11 candidates. Six ASEs (MRPL33, SIPA1L3, SNHG6, TPRG1, ZHX2, and ELOVL1) showed significant differential expression across both methods. Further evaluation of chromatin modification revealed that ASEs strongly correlated with cancer-specific distribution of acetylated lysine 27 of histone 3 (H3K27ac). Subsequent epigenetic treatment of HPV+ HNSCC cell lines (UM-SCC-047 and UPCI-SCC-090) with JQ1 not only induced downregulation of cancer-specific ASE isoforms, but also growth inhibition in both cell lines. The UPCI-SCC-090 cell line, with greater ASE expression, also showed more significant growth inhibition after JQ1 treatment. This study confirms several novel cancer-specific ASEs in HPV+OPSCC and provides evidence for the role of chromatin modifications in regulation of alternative splicing in HPV+OPSCC. This highlights the role of epigenetic changes in the oncogenesis of HPV+OPSCC, which represents a unique, unexplored target for therapeutics that can alter the global post-transcriptional landscape.

Entities:  

Keywords:  Human papillomavirus; alternative splicing; oropharyngeal cancer; super-enhancers

Year:  2020        PMID: 32164487      PMCID: PMC7518675          DOI: 10.1080/15592294.2020.1741757

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  42 in total

Review 1.  Epigenetic Mechanisms of Human Papillomavirus-Associated Head and Neck Cancer.

Authors:  Nicole V J Anayannis; Nicolas F Schlecht; Thomas J Belbin
Journal:  Arch Pathol Lab Med       Date:  2015-05-15       Impact factor: 5.534

2.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.

Authors:  Keisuke Enomoto; Xuguang Zhu; Sunmi Park; Li Zhao; Yuelin J Zhu; Mark C Willingham; Jun Qi; John A Copland; Paul Meltzer; Sheue-Yann Cheng
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

4.  Identifying ChIP-seq enrichment using MACS.

Authors:  Jianxing Feng; Tao Liu; Bo Qin; Yong Zhang; Xiaole Shirley Liu
Journal:  Nat Protoc       Date:  2012-08-30       Impact factor: 13.491

5.  MapSplice: accurate mapping of RNA-seq reads for splice junction discovery.

Authors:  Kai Wang; Darshan Singh; Zheng Zeng; Stephen J Coleman; Yan Huang; Gleb L Savich; Xiaping He; Piotr Mieczkowski; Sara A Grimm; Charles M Perou; James N MacLeod; Derek Y Chiang; Jan F Prins; Jinze Liu
Journal:  Nucleic Acids Res       Date:  2010-08-27       Impact factor: 16.971

6.  Expression microarray analysis reveals alternative splicing of LAMA3 and DST genes in head and neck squamous cell carcinoma.

Authors:  Ryan Li; Michael F Ochs; Sun Mi Ahn; Patrick Hennessey; Marietta Tan; Ethan Soudry; Daria A Gaykalova; Mamoru Uemura; Mariana Brait; Chunbo Shao; William Westra; Justin Bishop; Elana J Fertig; Joseph A Califano
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

7.  Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition.

Authors:  Alika K Maunakea; Iouri Chepelev; Kairong Cui; Keji Zhao
Journal:  Cell Res       Date:  2013-08-13       Impact factor: 25.617

8.  Comprehensive genomic characterization of head and neck squamous cell carcinomas.

Authors: 
Journal:  Nature       Date:  2015-01-29       Impact factor: 49.962

9.  Unique DNA methylation signature in HPV-positive head and neck squamous cell carcinomas.

Authors:  Davide Degli Esposti; Athena Sklias; Sheila C Lima; Stéphanie Beghelli-de la Forest Divonne; Vincent Cahais; Nora Fernandez-Jimenez; Marie-Pierre Cros; Szilvia Ecsedi; Cyrille Cuenin; Liacine Bouaoun; Graham Byrnes; Rosita Accardi; Anne Sudaka; Valérie Giordanengo; Hector Hernandez-Vargas; Luis Felipe Ribeiro Pinto; Ellen Van Obberghen-Schilling; Zdenko Herceg
Journal:  Genome Med       Date:  2017-04-05       Impact factor: 11.117

10.  Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis.

Authors:  Leilei He; Lixia Gao; Chloe Shay; Liwei Lang; Fenglin Lv; Yong Teng
Journal:  J Exp Clin Cancer Res       Date:  2019-02-18
View more
  9 in total

Review 1.  Epigenetic Regulations of Perineural Invasion in Head and Neck Squamous Cell Carcinoma.

Authors:  Pavel Hurník; Zuzana Chyra; Tereza Ševčíková; Jan Štembírek; Kateřina Smešný Trtková; Daria A Gaykalova; Marcela Buchtová; Eva Hrubá
Journal:  Front Genet       Date:  2022-04-27       Impact factor: 4.772

2.  Liquid lncRNA Biopsy for the Evaluation of Locally Advanced and Metastatic Squamous Cell Carcinomas of the Head and Neck.

Authors:  Izabela Łasińska; Tomasz Kolenda; Kacper Guglas; Magda Kopczyńska; Joanna Sobocińska; Anna Teresiak; Norbert Oksza Strzelecki; Katarzyna Lamperska; Andrzej Mackiewicz; Jacek Mackiewicz
Journal:  J Pers Med       Date:  2020-09-16

Review 3.  Abnormal Expression of Mitochondrial Ribosomal Proteins and Their Encoding Genes with Cell Apoptosis and Diseases.

Authors:  Guomin Huang; Hongyan Li; Hong Zhang
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

4.  Editorial: "Non-Coding RNAs in Head and Neck Squamous Cell Carcinoma".

Authors:  Wei Cao; Qiang Shen; Ming Yann Lim
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

Review 5.  High Risk-Human Papillomavirus in HNSCC: Present and Future Challenges for Epigenetic Therapies.

Authors:  Lavinia Ghiani; Susanna Chiocca
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

Review 6.  Alternative Splicing, Epigenetic Modifications and Cancer: A Dangerous Triangle, or a Hopeful One?

Authors:  Francisco Gimeno-Valiente; Gerardo López-Rodas; Josefa Castillo; Luis Franco
Journal:  Cancers (Basel)       Date:  2022-01-22       Impact factor: 6.639

7.  Tumor protein P63 Regulated 1 contributes to inflammation and cell proliferation of cystitis glandularis through regulating the NF-кB/cyclooxygenase-2/prostaglandin E2 axis.

Authors:  Tao Hong; Songzhe Piao; Liangxue Sun; Yiran Tao; Mang Ke
Journal:  Bosn J Basic Med Sci       Date:  2022-02-01       Impact factor: 3.363

Review 8.  Histone Marks-Dependent Effect on Alternative Splicing: New Perspectives for Targeted Splicing Modulation in Cancer?

Authors:  Carol Imbriano; Silvia Belluti
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

Review 9.  Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care.

Authors:  Haoru Dong; Xinhua Shu; Qiang Xu; Chen Zhu; Andreas M Kaufmann; Zhi-Ming Zheng; Andreas E Albers; Xu Qian
Journal:  Virol Sin       Date:  2021-06-21       Impact factor: 4.327

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.